David Hurd is an Oncology physician affiliated with Atrium Health Wake Forest Baptist. OpenAlex indexes 237 publications with 10,293 citations (h-index 44); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Medical Center Blvd
Winston-Salem, NC 27157
Telephone
336-716-2255Registry record last updated 23 May 2008.
Clinical trials
- Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy
Sponsor: Cristina Gasparetto
- Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases
Sponsor: Wake Forest University Health Sciences
- Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer
Sponsor: Wake Forest University Health Sciences
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20231 payment
- E.R. Squibb & Sons, L.L.C.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
3 NIH research awards on record, funded 1998–2010 per NIH RePORTER. The latest:
- CLINICAL TRIAL: SELENIUM AND VITAMIN E CANCER PREVENTION TRIAL (SELECT)
Wake Forest University Health Sciences
FY2010$8,078M01RR007122 - CLINICAL TRIAL: SELENIUM AND VITAMIN E CANCER PREVENTION TRIAL (SELECT)
Wake Forest University Health Sciences
FY2009$10,220M01RR007122
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma
New England Journal of Medicine
2022 - Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
New England Journal of Medicine
2012
Similar KOLs
Other experts from the same institution or the same specialty.
David Herrington, MD
Atrium Health Wake Forest Baptist
Bruce Lessey, MD
Atrium Health Wake Forest Baptist
Kevin High, MD
Atrium Health Wake Forest Baptist
David Browning, MD, PhD
Atrium Health Wake Forest Baptist
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”